Brosa M, Taylor MJ, Staginnus U, Meno Duran A, Cerri KH, Cervantes F. Cost-effectiveness of dasatinib vs imatinib 800 mg qd in patients with imatinib-resistant chronic myeloid leukemia in Spain. Value Health 2007;10:A283.PCN69 COST-EFFECTIVENESS ANALYSIS OF DASATINIB 100 MG VS. IMATINIB...
Objective: Purpose of this Italian economic analysis was to estimate the cost-effectiveness of dasatinib (100 mg/day) versus high-dose (800 mg/day) imatinib (HDI), in CP-CML patients, in the perspective of the Italian National Healthcare System (NHS). Design: The study applied a cost-effe...
Methods: Long-term cost-effectiveness of dasatinib (140 mg/day) vs. imatinib (800 mg/day) wasmodeled with a Markov model using initial best response from a randomized clinical trial in chronic-phase CML patients resistant to 400-600 mg imatinib. Model simulation runs in monthly cycles until ...
An economic analysis of high-dose imatinib, dasatinib, and nilotinib for imatinib-resistant chronic phase chronic myeloid leukemia in China: a CHEERS-compliant article. Medicine (Baltimore). 2017;96(29):e7445. doi:10.1097/MD.0000000000007445 PubMedGoogle Scholar 28. Remák E...
Cost-effectiveness of dasatinib versus high-dose imatinib in patients with Chronic Myeloid Leukemia (CML), resistant to standard dose imatinib – a Swedish model application[J] . Ola Ghatnekar,Frida Hjalte,Matthew Taylor.Acta Oncologica . 2010 (6)...
Using data for the licensed dose of 100 mg/day, dasatinib is estimated to be less expensive and more effective (dominant) compared with nilotinib (800 mg/day) and cost effective versus high dose imatinib with a cost/LY of €5,250 and a cost/QALY of €5,221. In CP-CML patients, who...
Cost-effectiveness analysis of dasatinib for the treatment of imatinib resistant or intolerant CML patients in Brazil. Value Health 2008;11:A64.DeRubeis RJ, Siegle GJ, Hollon SD. Cognitive therapy versus medication for depression: treatment outcomes and neural mechanisms . Nat Rev Neurosci (2008)...
Cost-Effectiveness Of First-Line Tyrosine Kinase Inhibitors (Tkis) In Newly Diagnosed Chronic Myeloid Leukemia (Cml) Patients In Korea: Comparison Of Dasatinib (100mg), Nilotinib (600mg) And Imatinib (400mg)[J] . M Shin,S Shin,JY Lee,J Kim,J Park,H Kwon.Value in Health . 2015 (7)...
Cost-effectiveness of dasatinib versus high-dose imatinib in patients with Chronic Myeloid Leukemia (CML), resistant to standard dose imatinib – a Swedish model application[J] . Ola Ghatnekar,Frida Hjalte,Matthew Taylor.Acta Oncologica . 2010 (6)...
Logman JFS, Taylor MJ, Neumann K, Kutikova L, Cerri KH, Van Houc BA, et al. Cost- utility analysis of dasatinib in patients after first-line failure of imatinib in chronic myeloid leukemia (CML) in Austria. Value Health 2007;10:A325....